ArticleCureus2025
Dermatomyositis, Rhabdomyolysis, and Statin-Induced Myopathy: A Case Report Illustrating the Spectrum of Myopathy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Advances in the Regulation by Immune Cells of Skeletal Myositis Outcomes.Aging and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report describes a rare presentation of rhabdomyolysis and dermatomyositis in a patient with existing statin-induced myopathy, presenting with acute-on-chronic kidney disease. The patient had an initial diagnosis of statin-induced myopathy through mild creatinine kinase elevation following the prescription of atorvastatin. However, eight months after this, she presented with fulminant rhabdomyolysis following the introduction of furosemide and omeprazole. Dermatomyositis was diagnosed concurrently through a clinical presentation of heliotrope rash and proximal muscle weakness, which was confirmed by muscle biopsy. As the patient was already in advanced kidney failure with features of fluid overload, aggressive treatment with intravenous fluids was withheld. After failing to respond to high-dose steroids, the patient was treated early with intravenous immunoglobulins, which resulted in a rapid drop in creatine kinase level, improvement of muscle weakness, and renal function. This study depicts the nuanced and idiosyncratic spectrum of myopathy through a progressive transition of symptoms over a defined timeframe. It also highlights the adverse interactions between proton pump inhibitors, diuretics, and statins in triggering rhabdomyolysis and unmasking the presentation of dermatomyositis. Furthermore, it demonstrates the therapeutic effects of early intervention with intravenous immunoglobulin as rescue therapy for rhabdomyolysis in a situation where conventional fluid resuscitation was limited by advanced kidney failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.